TITLE

Macroautophagy as a Target of Cancer Therapy

AUTHOR(S)
Lorin, S�verine; Codogno, Patrice; Djavaheri-Mergny, Mojgan
PUB. DATE
August 2007
SOURCE
Current Cancer Therapy Reviews;2007, Vol. 3 Issue 3, p199
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Macroautophagy (hereafter referred as to autophagy) is a vacuolar lysosomal degradative pathway for cytoplasmic macromolecules and organelles. There is growing evidence that autophagy is controlled by tumor-regulating molecules, and that it is downregulated during the early stages of tumorigenesis. Nevertheless, the relationship between autophagy and tumor progression seems to be complex, since in response to various stress situations, cancer cells are able to trigger autophagy either as a survival mechanism or conversely as a mechanism leading to cell death. Therefore, depending on the context, autophagy may trigger opposite outcomes in cancer cell fate. These two aspects of autophagy should be further taken into account in view of its possible modulation for cancer treatment.
ACCESSION #
25917278

 

Related Articles

  • Enhanced Therapeutic Efficacy by Simultaneously Targeting Two Genetic Defects in Tumors. He Zhang; Haibo Wang; Jianjun Zhang; Guanxiang Qian; Beibei Niu; Xianqun Fan; Jian Lu; Hoffman, Andrew R.; Ji-Fan Hu; Shengfang Ge // Molecular Therapy;Jan2009, Vol. 17 Issue 1, p57 

    Targeting tumor-specific gene abnormalities has become an attractive approach in developing therapeutics to treat cancer. Overexpression of Bcl2 and mutations of p53 represent two of the most common molecular defects in tumors. In the nucleus, p53 induces cell cycle arrest, while it interacts...

  • A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. Mellor, H. R.; Ferguson, D. J. P.; Callaghan, R. // British Journal of Cancer;8/8/2005, Vol. 93 Issue 3, p302 

    The quiescent cell population of tumours poses a barrier to the success of many cancer therapies. Most chemotherapeutic drugs target proliferating cells, but the growth fraction of many tumours is low. Based on the multicellular tumour spheroid model, a system was developed using human colon...

  • Promoting apoptosis as a strategy for cancer drug discovery. Fesik, Stephen W. // Nature Reviews Cancer;Nov2005, Vol. 5 Issue 11, p876 

    Apoptosis is deregulated in many cancers, making it difficult to kill tumours. Drugs that restore the normal apoptotic pathways have the potential for effectively treating cancers that depend on aberrations of the apoptotic pathway to stay alive. Apoptosis targets that are currently being...

  • In Brief.  // Nature Reviews Cancer;Sep2005, Vol. 5 Issue 9, p672 

    Cites several studies regarding the treatment of cancer. Correlation of HIF overexpression with biallelic loss of fumerate hydratase in renal cancer; Ability of clusterin to inhibit apoptosis; Efficacy of atelocollagen in vivo in delivering small interfering RNA to bone-metastatic tumors.

  • PATHWAYS OF APOPTOTIC AND NON-APOPTOTIC DEATH IN TUMOUR CELLS Childs, Oliver // Nature Reviews Cancer;Aug2004, Vol. 4 Issue 8, p592 

    Defects in cell-death pathways are hallmarks of cancer. Although resistance to apoptosis is closely linked to tumorigenesis, tumour cells can still be induced to die by non-apoptotic mechanisms, such as necrosis, senescence, autophagy and mitotic catastrophe. The molecular pathways that underlie...

  • Small Molecule Inhibitors of Stat3 Signaling Pathway. Jinxia Deng; Grande, Fedora; Neamati, Nouri // Current Cancer Drug Targets;Feb2007, Vol. 7 Issue 1, p91 

    Constitutive activation of the Signal Transducers and Activators of Transcription 3 (Stat3) meditated signaling pathway is very important for cell growth and survival. Compelling evidence from mechanistic studies with antisense, RNA interference (RNAi), peptides, and small molecular inhibitors...

  • The potential of TRAIL for cancer chemotherapy. Nagane, M.; Huang, H.-J. S.; Cavenee, W. K. // Apoptosis;Jun2001, Vol. 6 Issue 3, p191 

    Innate and acquired resistance to chemotherapy and radiation therapy has been a major obstacle for clinical oncology. One potential adjunct to such conventional treatments is direct induction of cell death by activation of death receptor-mediated apoptosis. TRAIL (tumor necrosis factor...

  • TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Wajant, H.; Pfizenmaier, K.; Scheurich, P. // Apoptosis;Oct2002, Vol. 7 Issue 5, p449 

    TNF-related apoptosis-inducing ligand (TRAIL/APO-2L) is a typical member of the TNF ligand family that induces apoptosis by activating the death receptors TRAIL-R1 and TRAIL-R2. TRAIL has attracted great attention in recent years as a promising anti cancer reagent because recombinant soluble...

  • The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness. Zhiwei Wang; Yiwei Li; Dejuan Kong; Sarkar, Fazlul H. // Current Drug Targets;Jun2010, Vol. 11 Issue 6, p745 

    The Notch signaling pathway maintains a balance between cell proliferation and apoptosis, and thus it is believed that Notch signaling pathway may play an important role in the development and progression of several malignancies. However, the functions of Notch signaling in EMT are largely...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics